The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 4:18 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #25. Myriad Genetics, Inc. Crescendo Bioscience

Acquirer: Myriad Genetics, Inc. (NASDAQ:MYGN)
Acquiree: Crescendo Bioscience
Details: Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has entered into a definitive agreement to acquire Crescendo Bioscience, Inc., a global leader in autoimmune diagnostics, for $270 million in cash which will be reduced by $25 million for the repayment of a loan made to Crescendo and customary adjustments in accordance with the acquisition agreement.

Myriad Genetics is precision medicine company acting as an advisor to transform patient lives through molecular diagnostics. Co.'s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual's risk for developing disease later in life, diagnose disease, determine a patient's likelihood of responding to a particular drug, or disease recurrence and assess a patient's risk of disease progression. Co. also provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology.

MYGN SEC Filing Email Alerts Service


Open the MYGN Page at The Online Investor »

Company Name: 
Myriad Genetics, Inc.
Stock buyback: 
MYGN buyback
Website: 
www.myriad.com
Sector: 
Biotechnology
Number of ETFs Holding MYGN: 
45
Total Market Value Held by ETFs: 
$530.63M
Total Market Capitalization: 
$2.19B
% of Market Cap. Held by ETFs: 
24.19%
 

Open the MYGN Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Hold (1.50 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts' Target Price:
MYGN Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 25 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.